Skip to main content

Table 1 Patient characteristics according to pathological response

From: Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer

Characteristics

All (n = 40)

Number (%)

pCR (n = 21)

Number (%)

Non-pCR (n = 19) Number (%)

P-value

Age at diagnosis (median, y)

50.5

51

50.0

0.935

≥ 50

21 (52.5)

11 (52.4)

10 (52.6)

0.987

< 50

19 (47.5)

10 (47.6)

9 (47.4)

 

Menopausal status

   

0.516

Pre-

21 (52.5)

10 (47.6)

11 (57.9)

 

Post-

19 (47.5)

11 (52.4)

8 (42.1)

 

Laterality

   

0.726

Left

18 (45.0)

10 (47.6)

8 (42.1)

 

Right

22 (55.0)

11 (52.4)

11 (57.9)

 

T stage*

   

0.105

cT1

1 (2.5)

0 (0)

1 (5.3)

 

cT2

21 (52.5)

9 (42.9)

12 (63.1)

 

cT3

9 (22.5)

5 (23.8)

4 (21.1)

 

cT4

9 (22.5)

7 (33.3)

2 (10.5)

 

N stage#

   

0.666

cN1

14 (35.0)

8 (38.1)

6 (31.6)

 

cN2

18 (45.0)

8 (38.1)

10 (52.6)

 

cN3

8 (20.0)

5 (23.8)

3 (15.8)

 

ER

   

0.115

Positive

29 (72.5)

13 (61.9)

16 (84.2)

 

Negative

11 (27.5)

8 (38.1)

3 (18.8)

 

PR

   

0.119

Positive

18 (45.0)

7 (33.3)

11 (57.9)

 

Negative

22 (55.0)

14 (66.7)

8 (42.1)

 

Ki67

   

1.000

≥ 20

35 (87.5)

18 (85.7)

17 (89.4)

 

< 20

5 (12.5)

3 (14.3)

2 (10.5)

 
  1. Notes * cT1–2 vs. cT3–4; # cN1 vs. cN2-3